Morpholino oligonucleotides useful in cancer treatment
US11679121B2 · kind B2 · utility
0Cited by
10References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 7, 2020 |
| Grant date | Jun 20, 2023 |
| Priority date | — |
| Expiry date | Jul 29, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4162
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.